Category: blood cancer

  • FDA slaps hold on trials of Gilead’s CD47 drug magrolimab

    The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences’ magrolimab, the centre piece of its $4.9 billion acquisition of Forty Seven in 2020. The regulatory move applies only to trials of magrolimab given alongside Bristol-Myers Squibb’s Vidaza (azacitidine), and stems from an “imbalance” in investigator-reported serious adverse events between study […]

  • J&J bulks up in bispecifics with $1.3bn Xencor alliance

    Fresh from claiming its first bispecific antibody approval, Johnson & Johnson has delved deeper into the category with a deal to license a drug for B-cell cancers developed by Xencor. J&J’s Janssen Biotech unit is paying $100 million upfront to Xencor and making a $25 million equity investment in the biotech in return for rights […]

  • Blood Cancer UK: Hopes for our community’s future in the time of COVID

    This thought leadership series has been paid and developed by Kite, a Gilead Company. This Blood Cancer Awareness Month, Blood Cancer UK’s Kate Keightley explains the need for better awareness and understanding of this common, but less-understood disease. Blood cancer is the fifth most common cancer in the UK and the third most deadly, killing […]

  • Gamble by Takeda on unproven cancer mechanism draws a blank

    Takeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor – has failed to show a benefit in patients with blood cancers, placing its future in doubt. The PANTHER trial looked at the combination of pevonedistat in combination with azacitidine chemotherapy as first-line treatment for patients with higher-risk […]

  • Dr. Amit Agarwal Interview

    Sonam: Hello everyone, today we have on our panel discussion round doctor Amit Agarwal with us who is Director Medical Oncology from Fortis Hospital Shalimar Bagh. We welcome your doctor on board. Dr. Amit: Thank you Sonam: So to let you know about Doctor Amit. Doctor Amit brings with him an experience of more than […]

  • TG Therapeutics completes FDA filing for Roche challenger in CLL

    TG Therapeutics has completed its rolling FDA filing for its U2 combination therapy consisting of the antibody ublituximab with the oral drug Ukoniq (umbralisib) as a treatment for chronic lymphocytic leukaemia (CLL). The US pharma is mounting a challenge to Roche, which markets an antibody therapy, Gazyvaro (obinutuzumab) in advanced CLL. Like Gazyvaro, ublituximab targets […]

  • TG Therapeutics challenges Roche with FDA filing for CLL drug

    US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche. The New York-based firm has requested approval for the combination of its anti-CD20 antibody ublituximab and umralisib, an oral drug that inhibits PI3K-delta and CK-1 epsilon. The FDA had already […]